At a glance
| Qsymia | Xenical | |
|---|---|---|
| Form | Daily capsule | 3x daily with meals |
| How often | Daily oral capsule — no injection | Three capsules daily, taken with each fat-containing meal |
| Weight loss in trials | Up to 9.8% — CONQUER (56 weeks) | Up to 8.5% — Sjostrom 1-year RCT (52 weeks) |
| FDA approved | 2012 | 1999 |
| Made by | Vivus | Roche (Xenical) / GSK (Alli OTC) |
| How it works | Phentermine suppresses appetite by triggering the release of adrenaline-like chemicals in the brain's hunger control centre. | Blocks pancreatic lipase enzymes in the small intestine, preventing approximately 30% of dietary fat from being broken down and absorbed. |
| Monthly cost, self-pay | $30–$400/mogeneric; brand runs to $400 | $40–$400/moover-the-counter strength; prescription runs to $400 |
| Most reported reaction | Dry mouth 21% (CONQUER) | Oily/fatty stools (steatorrhoea) 27% (XENDOS) |
Every figure in this table is read from the same trial and label records used everywhere else on this site.
Weight loss in each drug's main trial
No head-to-head trial has compared these two drugs.
CONQUER (56 weeks)
Sjostrom 1-year RCT (52 weeks)
In clinical trials, participants taking phentermine / topiramate ER lost on average up to 9.8% of their starting body weight, and participants taking orlistat lost on average up to 8.5%. Those numbers come from two different studies: CONQUER enrolled 2,487 adults with obesity and at least 2 weight-related health conditions over 56 weeks against placebo, while Sjostrom 1-year RCT enrolled 743 adults with obesity over 1 year (52 weeks) against placebo. Who took part, how long each trial ran and what each drug was measured against all move the percentage, so the two figures are not a measured difference between the drugs.
Monthly cost, self-pay
The bar spans the range in each drug's price record — lowest listed price to highest.
generic; brand runs to $400
~$30–$80/month generic; ~$200–$400/month brand (Qsymia).
over-the-counter strength; prescription runs to $400
Prescription Xenical ~$200–$400/month; over-the-counter Alli (60mg) ~$40–$60/month.
Self-pay prices are what the manufacturer or the pharmacy lists, not what most people end up paying. Qsymia: $30–$400/month. Xenical: $40–$400/month. Insurance, dose and pharmacy all change both figures.
Side effects reported in the trials
CONQUER and XENDOS did not report the same reactions, so there is no shared row to line up. Each drug's own reported rates are listed below.
- Paraesthesia (tingling in hands/feet)20%
- Dry mouth21%
- Constipation17%
- Insomnia10%
- Dizziness9%
- Cognitive effects ('brain fog')8%
From CONQUER
- Oily/fatty stools (steatorrhoea)27%
- Faecal urgency22%
- Oily spotting on underwear27%
- Faecal incontinence8%
- Abdominal pain/discomfort14%
From XENDOS
A rate is the share of trial participants who reported that reaction, not a prediction for any one person.
How they differ in practice
How you take it
- Qsymia — Once-daily extended-release capsule
- Xenical — Oral capsule 120 mg, three times daily with meals (prescription). Also available OTC as Alli at 60 mg.
Dose build-up
- Qsymia — 3.75/23 mg → 15/92 mg, titrated over 14 weeks
Where a drug is not listed here, its prescribing information sets out its own dose steps.
How soon it acts
- Qsymia — Appetite suppression typically begins within the first week; significant weight loss by 12–16 weeks
- Xenical — Weight effects begin from the first week (related to calorie malabsorption), but significant loss takes 8–12 weeks
Heart and metabolic findings
- Qsymia — In CONQUER, significant reductions in blood pressure, waist circumference, triglycerides, and blood glucose were observed.
- Xenical — In the 4-year XENDOS trial, orlistat reduced progression from prediabetes to type 2 diabetes by 37% compared to placebo plus lifestyle changes.
As stated in each drug’s trial record — not a claim about which drug protects the heart more.
Other findings recorded
- Qsymia — Generic now available (from 2025) — significantly lower cost than GLP-1 drugs; improved blood pressure and triglycerides in CONQUER trial
- Xenical — 37% reduction in progression to type 2 diabetes (XENDOS, 4 years); only approved obesity drug with a 4-year safety dataset
If you stop taking it
- Qsymia — Weight regain after stopping is expected.
- Xenical — Weight is typically regained after stopping.
Common questions
Written and maintained by one person · Built with agentic AI tools · Every number checked against the cited trial · Not medical advice
Clinical evidence — Phentermine / Topiramate ER and Orlistat
No head-to-head trial has compared these two drugs.
- CONQUER — Phentermine / Topiramate: 2,487 adults with obesity and at least 2 weight-related health conditions, 56 weeks. The Lancet, 2011. View source ↗
- Sjostrom 1-year RCT — Orlistat: 743 adults with obesity, 1 year (52 weeks). International Journal of Obesity, 2000. View source ↗
- XENDOS — Orlistat: 3,305 adults with obesity, including those with prediabetes, 4 years (208 weeks). Diabetes Care, 2004. View source ↗
- Qsymia (phentermine and topiramate extended-release) — FDA prescribing information — DailyMed View source ↗
- Xenical (orlistat) — FDA prescribing information — DailyMed View source ↗
Next step most people take
Built with agentic AI tools and not a substitute for medical advice
Last reviewed: